| Dr Lalji S Chudasama, MD | |
|
1101 Raritan Rd, Clark, NJ 07066-1315 | |
| (732) 381-3055 | |
| (732) 815-9330 |
| Full Name | Dr Lalji S Chudasama |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 56 Years |
| Location | 1101 Raritan Rd, Clark, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174519250 | NPI | - | NPPES |
| 2989409 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 25MA03264200 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jfk Medical Center | Edison, NJ | Hospital |
| Robert Wood Johnson University Hospital At Rahway | Rahway, NJ | Hospital |
| Morristown Medical Center | Morristown, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hackensack Meridian Health Medical Group - Specialty Care Pc | 9133032519 | 1090 |
News Archive
Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin's lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.
The International Narcotics Control Board "remains out of step" with the rest of the United Nations' efforts to fight the spread of HIV, especially among injection drug users, and its practices should be open for review, Joanne Csete of the Canadian HIV/AIDS Legal Network and Daniel Wolfe, deputy director of Open Society Institute's International Harm Reduction Development program, write in a Lancet opinion piece.
The ATS has released an official policy statement of pay-for-performance (P4P) in pulmonary, critical care and sleep medicine. In the statement, the Society encourages clinicians in these fields to participate in P4P programs and views them as an opportunity to partner with healthcare payors, accrediting organizations, governmental oversight groups and others to improve quality, rather than as a threat to autonomy and independence.
The U.S. Preventive Services Task Force (USPSTF) now recommends the hepatitis C virus (HCV) infection screening for adults in the age group 18 to 79 years. This update comes against the background of increasing HCV over the last ten years, primarily due to higher injection drug use, and closer monitoring. The recommendation ensures that this screening will be covered by insurance as well without cost-sharing.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.
› Verified 1 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin's lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.
The International Narcotics Control Board "remains out of step" with the rest of the United Nations' efforts to fight the spread of HIV, especially among injection drug users, and its practices should be open for review, Joanne Csete of the Canadian HIV/AIDS Legal Network and Daniel Wolfe, deputy director of Open Society Institute's International Harm Reduction Development program, write in a Lancet opinion piece.
The ATS has released an official policy statement of pay-for-performance (P4P) in pulmonary, critical care and sleep medicine. In the statement, the Society encourages clinicians in these fields to participate in P4P programs and views them as an opportunity to partner with healthcare payors, accrediting organizations, governmental oversight groups and others to improve quality, rather than as a threat to autonomy and independence.
The U.S. Preventive Services Task Force (USPSTF) now recommends the hepatitis C virus (HCV) infection screening for adults in the age group 18 to 79 years. This update comes against the background of increasing HCV over the last ten years, primarily due to higher injection drug use, and closer monitoring. The recommendation ensures that this screening will be covered by insurance as well without cost-sharing.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.
› Verified 1 days ago
| Entity Name | Community Hospital Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225251754 PECOS PAC ID: 3971415209 Enrollment ID: O20031120000589 |
News Archive
Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin's lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.
The International Narcotics Control Board "remains out of step" with the rest of the United Nations' efforts to fight the spread of HIV, especially among injection drug users, and its practices should be open for review, Joanne Csete of the Canadian HIV/AIDS Legal Network and Daniel Wolfe, deputy director of Open Society Institute's International Harm Reduction Development program, write in a Lancet opinion piece.
The ATS has released an official policy statement of pay-for-performance (P4P) in pulmonary, critical care and sleep medicine. In the statement, the Society encourages clinicians in these fields to participate in P4P programs and views them as an opportunity to partner with healthcare payors, accrediting organizations, governmental oversight groups and others to improve quality, rather than as a threat to autonomy and independence.
The U.S. Preventive Services Task Force (USPSTF) now recommends the hepatitis C virus (HCV) infection screening for adults in the age group 18 to 79 years. This update comes against the background of increasing HCV over the last ten years, primarily due to higher injection drug use, and closer monitoring. The recommendation ensures that this screening will be covered by insurance as well without cost-sharing.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.
› Verified 1 days ago
| Entity Name | Hmh Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356016661 PECOS PAC ID: 9032181847 Enrollment ID: O20220304001385 |
News Archive
Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin's lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.
The International Narcotics Control Board "remains out of step" with the rest of the United Nations' efforts to fight the spread of HIV, especially among injection drug users, and its practices should be open for review, Joanne Csete of the Canadian HIV/AIDS Legal Network and Daniel Wolfe, deputy director of Open Society Institute's International Harm Reduction Development program, write in a Lancet opinion piece.
The ATS has released an official policy statement of pay-for-performance (P4P) in pulmonary, critical care and sleep medicine. In the statement, the Society encourages clinicians in these fields to participate in P4P programs and views them as an opportunity to partner with healthcare payors, accrediting organizations, governmental oversight groups and others to improve quality, rather than as a threat to autonomy and independence.
The U.S. Preventive Services Task Force (USPSTF) now recommends the hepatitis C virus (HCV) infection screening for adults in the age group 18 to 79 years. This update comes against the background of increasing HCV over the last ten years, primarily due to higher injection drug use, and closer monitoring. The recommendation ensures that this screening will be covered by insurance as well without cost-sharing.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lalji S Chudasama, MD 1101 Raritan Rd, Clark, NJ 07066-1315 Ph: (732) 381-3055 | Dr Lalji S Chudasama, MD 1101 Raritan Rd, Clark, NJ 07066-1315 Ph: (732) 381-3055 |
News Archive
Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin's lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.
The International Narcotics Control Board "remains out of step" with the rest of the United Nations' efforts to fight the spread of HIV, especially among injection drug users, and its practices should be open for review, Joanne Csete of the Canadian HIV/AIDS Legal Network and Daniel Wolfe, deputy director of Open Society Institute's International Harm Reduction Development program, write in a Lancet opinion piece.
The ATS has released an official policy statement of pay-for-performance (P4P) in pulmonary, critical care and sleep medicine. In the statement, the Society encourages clinicians in these fields to participate in P4P programs and views them as an opportunity to partner with healthcare payors, accrediting organizations, governmental oversight groups and others to improve quality, rather than as a threat to autonomy and independence.
The U.S. Preventive Services Task Force (USPSTF) now recommends the hepatitis C virus (HCV) infection screening for adults in the age group 18 to 79 years. This update comes against the background of increasing HCV over the last ten years, primarily due to higher injection drug use, and closer monitoring. The recommendation ensures that this screening will be covered by insurance as well without cost-sharing.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.
› Verified 1 days ago
Mr. Brandt Mitchell Levin, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 100 Commerce Pl, Clark, NJ 07066 Phone: 732-388-5757 Fax: 732-499-8128 | |
Asha M Vijayakumar, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 152 Central Ave, Clark, NJ 07066 Phone: 732-382-9700 Fax: 732-382-9707 | |
Allison Guttmann Lewis, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 140 Central Ave, Clark, NJ 07066 Phone: 732-943-5038 | |
Dr. Cheng-hong Hwang, D.O., PH. D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1457 Raritan Rd, Clark, NJ 07066 Phone: 908-272-2270 Fax: 908-272-0558 | |
Dr. Irene Cho, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 67 Walnut Ave Ste 310, Clark, NJ 07066 Phone: 908-654-3377 | |
Sheila Sahni, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 53-59 Westfield Ave, Clark, NJ 07066 Phone: 732-396-9500 Fax: 732-382-1377 |